CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

医学 心力衰竭 射血分数 脑啡肽酶 沙库比林 背景(考古学) 缬沙坦 血管紧张素受体 重症监护医学 心脏病学 内科学 地高辛 药理学 血管紧张素II 受体 血压 古生物学 生物化学 化学 生物
作者
Michael McDonald,Sean Virani,Michael Chan,Anique Ducharme,Justin A. Ezekowitz,Nadia Giannetti,George A. Heckman,Jonathan G. Howlett,Sheri L. Koshman,Serge Lepage,Lisa Mielniczuk,Gordon W. Moe,Eileen O’Meara,Elizabeth Swiggum,Mustafa Toma,Shelley Zieroth,Kim B. Anderson,Sharon Bray,Brian Clarke,Alain Cohen‐Solal,Michel D’Astous,Margot K. Davis,Sabe De,Andrew Grant,Adam Grzeslo,Jodi Heshka,Sabina Keen,Simon Kouz,Douglas S. Lee,Frederick A. Masoudi,Robert S. McKelvie,Marie-Claude Parent,Stephanie Poon,Miroslaw Rajda,Abhinav Sharma,Kyla Siatecki,Kate Storm,Bruce Sussex,Harriette G.C. Van Spall,Amelia Yip
出处
期刊:Canadian Journal of Cardiology [Elsevier BV]
卷期号:37 (4): 531-546 被引量:175
标识
DOI:10.1016/j.cjca.2021.01.017
摘要

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we provide comprehensive recommendations and practical tips for the pharmacologic management of patients with HF with reduced ejection fraction (HFrEF). Since the 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of HF, substantial new evidence has emerged that has informed the care of these patients. In particular, we focus on the role of novel pharmacologic therapies for HFrEF including angiotensin receptor-neprilysin inhibitors, sinus node inhibitors, sodium glucose transport 2 inhibitors, and soluble guanylate cyclase stimulators in conjunction with other long established HFrEF therapies. Updated recommendations are also provided in the context of the clinical setting for which each of these agents might be prescribed; the potential value of each therapy is reviewed, where relevant, for chronic HF, new onset HF, and for HF hospitalization. We define a new standard of pharmacologic care for HFrEF that incorporates 4 key therapeutic drug classes as standard therapy for most patients: an angiotensin receptor-neprilysin inhibitor (as first-line therapy or after angiotensin converting enzyme inhibitor/angiotensin receptor blocker titration); a β-blocker; a mineralocorticoid receptor antagonist; and a sodium glucose transport 2 inhibitor. Additionally, many patients with HFrEF will have clinical characteristics for which we recommended other key therapies to improve HF outcomes, including sinus node inhibitors, soluble guanylate cyclase stimulators, hydralazine/nitrates in combination, and/or digoxin. Finally, an approach to management that integrates prioritized pharmacologic with nonpharmacologic and invasive therapies after a diagnosis of HFrEF is highlighted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
科目三应助彭栋采纳,获得10
5秒前
方文浩发布了新的文献求助10
5秒前
ding应助YWang采纳,获得10
8秒前
8秒前
林宝雯关注了科研通微信公众号
13秒前
16秒前
斯文败类应助GGBOND采纳,获得10
16秒前
星辰大海应助科研通管家采纳,获得10
16秒前
李健的小迷弟应助GGBOND采纳,获得10
16秒前
上官若男应助科研通管家采纳,获得10
16秒前
17秒前
大模型应助科研通管家采纳,获得10
17秒前
圆锥香蕉应助科研通管家采纳,获得20
17秒前
星辰大海应助科研通管家采纳,获得10
17秒前
17秒前
17秒前
Bio应助科研通管家采纳,获得30
17秒前
科研通AI5应助科研通管家采纳,获得10
17秒前
斯文败类应助科研通管家采纳,获得10
17秒前
汉堡包应助科研通管家采纳,获得10
17秒前
18秒前
21秒前
23秒前
23秒前
Dotson发布了新的文献求助10
24秒前
sinsinsin发布了新的文献求助10
25秒前
CodeCraft应助娇气的天亦采纳,获得10
26秒前
27秒前
权思远发布了新的文献求助10
27秒前
彭栋发布了新的文献求助10
27秒前
量子星尘发布了新的文献求助10
28秒前
李爱国应助收集快乐采纳,获得10
29秒前
守墓人完成签到 ,获得积分10
30秒前
31秒前
科研通AI5应助xiaoxiao采纳,获得10
34秒前
顾矜应助权思远采纳,获得10
34秒前
苯氮小羊完成签到,获得积分10
34秒前
36秒前
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989115
求助须知:如何正确求助?哪些是违规求助? 3531367
关于积分的说明 11253688
捐赠科研通 3269986
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882078
科研通“疑难数据库(出版商)”最低求助积分说明 809105